From: A potential role for intragenic miRNAs on their hosts' interactome
Pathway | Host Genes in Pathway | Target Coverage | p-Value | q-Value |
---|---|---|---|---|
MAPK Signaling | ATF2; DDIT3; AKT2; FGF13; ARRB1; PPP3CA; PRKCA; CACNG8; RPS6KA2; MAP2K4; RPS6KA4 | 61.4% | < 0.001 | < 0.001 |
Axon Guidance | PPP3CA; PTK2; SEMA4G; SEMA3F; SLIT3; ABLIM2; SLIT2 | 70.3% | < 0.001 | < 0.001 |
Ubiquitin Mediated Proteolysis | HUWE1; WWP2; BIRC6; ITCH | 53.8% | < 0.001 | < 0.001 |
Focal Adhesion | COL3A1; AKT2; PRKCA; PTK2; TLN2 | 49.5% | < 0.001 | < 0.001 |
Glioma | AKT2; PRKCA | 52.3% | < 0.001 | < 0.001 |
Melanoma | AKT2; FGF13 | 50.7% | < 0.001 | < 0.001 |
Regulation of Actin Cytoskeleton | CHRM2; FGF13; SSH1; PTK2 | 41.0% | < 0.001 | < 0.001 |
Chronic Myloid Leukemia | AKT2 | 38.2% | < 0.001 | < 0.001 |
Colorectal Cancer | AKT2 | 35.7% | < 0.001 | < 0.001 |
Prostate Cancer | AKT2 | 34.8% | 0.001 | 0.007 |
Melanogenesis | PRKCA | 21.6% | 0.001 | 0.007 |
Pancreatic Cancer | AKT2 | 35.6% | 0.002 | 0.01 |
ErbB Signaling | ERBB4; AKT2; PRKCA; PTK2; MAP2K4 | 51.7% | 0.003 | 0.02 |
Glycan Structures Biosynthesis | MGAT4B; FUT8; CSGLCA-T; GALNT10; HS3ST3A1 | 50.8% | 0.003 | 0.02 |
Gap Junction | HTR2C; PRKCA; PRKG1 | 47.9% | 0.005 | 0.02 |
Non-Small Cell Lung Cancer | AKT2; PRKCA | 42.6% | 0.007 | 0.03 |
Small Cell Lung Cancer | AKT2; PTK2 | 35.6% | 0.013 | 0.05 |
Long-Term Depression | PRKCA; PRKG1 | 33.3% | 0.014 | 0.05 |
Insulin Signaling | AKT2; SREBF1 | 36.0% | 0.014 | 0.05 |
Long-Term Potentiation | PPP3CA; PRKCA; RPS6KA2 | 27.1% | 0.005 | 0.06 |
T-Cell Receptor Signaling | AKT2; PPP3CA | 32.3% | 0.016 | 0.09 |
Wnt Signaling | PPP3CA; PRKCA | 21.6% | 0.020 | 0.09 |